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Both  COPD  and  lung  cancer  are  major  worldwide  health  concerns  owing  to cigarette  smoking,  and  rep-
resent  a huge,  worldwide,  preventable  disease  burden.  Whilst  the majority  of smokers  will not  develop
either  COPD  or  lung  cancer,  they  are  closely  related  diseases,  occurring  as  co-morbidities  at  a higher  rate
than if they  were  independently  triggered  by  smoking.
Lung  cancer  and  COPD  may  be  different  aspects  of  the  same  disease,  with  the  same  underlying  pre-
dispositions,  whether  this  is  an  underlying  genetic  predisposition,  telomere  shortening,  mitochondrial
dysfunction  or premature  aging.  In  the  majority  of  smokers,  the burden  of  smoking  may  be dealt  with  by
the body’s  defense  mechanisms:  anti-oxidants  such  as  superoxide  dismutases,  anti-proteases  and  DNA
repair mechanisms.  However,  in  the  case  of  both  diseases  these  fail,  leading  to  cancer  if mutations  occur
or COPD  if  damage  to the  cell  and  proteins  becomes  too  great.Alternatively  COPD  could  be a driving  factor  in  lung  cancer,  by increasing  oxidative  stress  and  the
resulting  DNA  damage,  chronic  exposure  to  pro-inﬂammatory  cytokines,  repression  of  the  DNA  repair
mechanisms  and  increased  cellular  proliferation.  Understanding  the  mechanisms  that drive  these  pro-
cesses  in  primary  cells  from  patients  with these  diseases  along  with  better  disease  models  is essential
for  the development  of  new  treatments.
© 2015  The  Authors.  Published  by  Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the  CC  BY
license  (http://creativecommons.org/licenses/by/4.0/).. Introduction
Tobacco smoking originated in the Mayan kingdom in 600–900
D [1] before spreading across the globe with the advent of cross-
tlantic trade and particularly the invention of pre-rolled cigarettes
n the late 19th century. Thus, smoking rates increased globally
rom <0.5% of the USA population from the start of the 20th cen-
ury peaking in 1965 with 50% of men  and 33% of women  who
moked [2]. The increase in smoking correlated with an increase in
he incidence of lung cancer [3].
Approximately 50% of smokers will have their lives curtailed by
igarettes: each cigarette smoked reduces life expectancy by 11 min
uch that males and females each lose an average of 13.2 and 14.5
ears of life, respectively [2]. From 2000–2004 in the USA alone,
443,000 adults died due to cigarette smoking-related diseasesncluding lung cancer (125,522), coronary heart disease (80,005)
nd COPD and other airway obstructive diseases (78,988) [2].
∗ Corresponding author. Airways Disease Section, National Heart & Lung Institute,
ovehouse Street, London, SW3  6LY, UK. Fax: +44 20 7351 8126.
E-mail address: a.durham@imperial.ac.uk (A.L. Durham).
ttp://dx.doi.org/10.1016/j.lungcan.2015.08.017
169-5002/© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access 2. Lung cancer
The lifetime risk of developing lung cancer is 17.2% for males
and 11.6% for females in smokers compared with 1.3% and
1.4% respectively for non-smokers [4]. Lung cancer is the lead-
ing cause of cancer-related death worldwide [5,6] with only a
16% 5-year survival rate [7], The number of lung cancer deaths
is expected to rise to ten million deaths per year by 2030
[5].
Lung cancer is caused by mutations in oncogenes leading to
the proliferation of the mutated cells and the formation of a
tumor. Additional mutations can further transform the benign
tumor to an invasive cancer, a process marked by metastatis
(spread), invasiveness and anaplasia (loss of cell type speciﬁc fea-
tures) [8]. Lung cancers usually originate from the basal epithelial
cells and are classiﬁed into two types, non-small cell lung can-
cer (NSCLC) and small cell lung cancer (SCLC). NSCLC accounts
for approximately 85% of lung cancer cases [9] with adenocarci-
noma accounting for 40% of the total and large cell carcinoma for
5–10%. The remaining NSCLC (30%) derive from squamous cells.
The other cancers are termed small cell lung carcinomas (SCLC),
which are composed of smaller than normal, undifferentiated cells
[8].
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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. COPD
COPD is a progressive and ultimately fatal deterioration of lung
unction over time [10]. COPD has a marked effect on a patient’s
uality of life affecting up to 50% of smokers [11]. COPD was the
hird most common cause of death worldwide in 2010 [12] and
anked ﬁfth worldwide in terms of burden of disease [10].
Damage to the lungs in COPD is caused by oxidative stress (both
xogenous from smoking and endogenous), inﬂammatory cytokine
elease, protease activity (due to the protease: anti-protease imbal-
nce) and autoantibody expression [13]. These in turn can lead to
irway destruction, air trapping and lung hyperinﬂation.
. COPD and lung cancer are linked diseases
COPD and lung cancer are caused by cigarette smoking and there
s increasing evidence linking the two diseases beyond a common
tiology. COPD is an independent risk factor for lung carcinoma,
articularly for squamous cell carcinoma [14] and lung cancer is up
o ﬁve times more likely to occur in smokers with airﬂow obstruc-
ion than those with normal lung function [15]. Even excluding
actors such as over diagnosis COPD patients still have twice the
isk of lung cancer development [16]. The high prevalence of lung
ancer in COPD suggests that there may  be common mechanisms,
uch as premature aging in the lungs, genetic predispositions to
ither disease or common pathogenic factors, such as growth fac-
ors, activation of intracellular pathways or epigenetics. [17].
. Lung cancer and COPD: Diseases of the aging lung
The probability of developing cancer increases with age [18] and
he median age of onset for lung cancer is 66 years old [19]. COPD
rincipally affects smokers aged over 40 and is 2.5 times higher in
ver 60 year olds [11]. The normal decline in lung function with age-
ng is accelerated in patients with COPD leading to premature loss of
ung function [20,21]. Aging is principally driven by failure of organs
o repair DNA damage by oxidative stress (non-programmed aging)
nd from telomere shortening as a result of repeated cell division
programmed aging). These defects are both present in COPD [22].
. Oxidative stress is a causative agent of both diseases
Cigarettes contain approximately 1015 free radicals per puff
23,24], including reactive nitrogen and oxygen species (RNOS)
25]. In addition to exogenous RNOS, mitochondrial respiration is a
ajor source of RNOS generation and mitochondrial dysfunction is
resent in many cancers [26]. RNOS damage cells through a number
f mechanisms including DNA damage (especially mitochondrial
NA) lipid peroxidation, oxidation of amino acids and oxidation of
norganic enzyme co-factors.
.1. Oxidative stress damages DNA
The free radical hypothesis of aging proposes that RNOS drives
he accumulation of cell and DNA damage [27] and elevated levels
f oxidative stress are seen in many cancers [22,28–33]. Oxidative
tress drives cancer initiation through DNA damage: point muta-
ions, single stand breaks (SSBs) and double strand breaks (DSBs)
nd DNA cross-linking [28,34], which if incorrectly repaired, results
n mutations. The number of somatic mutations, which lead to
ancer, accumulates with age in part due to continuous RNOS expo-
ure. Hydroxyl radicals and peroxinitrate are especially implicated
n DNA damage [33] (Fig. 1). RNOS can lead to the degradation of
roteins, including tumor suppressors leading to cell division and
ecreasing apoptosis and DNA repair [33].ancer 90 (2015) 121–127
RNOS also plays a role in cancer promotion and progression
[35]. RNOS is an intracellular signal and activates proliferative and
inﬂammatory pathways, including the c-Jun N-terminal kinases
(JNK) dependent mitogen activate protein kinase (MAPK) pathway
which, in turn, drive proliferation [36]. Growth factor signal trans-
duction via RNOS is associated with oxidation of thiol groups of
tyrosine phosphatases, which results in their reversible inactiva-
tion and facilitates proliferation [36]. Additionally NO can increase
angiogenesis through vascular endothelial growth factor (VEGF)
stimulation and increases tumor growth and cell invasion prop-
erties [37].
6.2. Oxidative stress causes inﬂammation
RNOS also stimulates the production of inﬂammatory mediators
either directly [38] or indirectly [39]. Cells directly detect RNOS via
the ROS receptor/proto-oncogene ROS1 [40]. ROS1 activates the
phosphoinositide 3-kinase (PI3K)-mTOR signaling pathway [41]
and other proteins related to cell differentiation, proliferation,
growth and survival including AKT1, MAPK1, MAPK3, IRS1 and
PLCG2. Furthermore, ROS activates NF-B thereby upregulating the
expression of numerous immune and inﬂammatory genes [42].
RNOS can alter protein structure and function by modifying
amino acid residues, inducing protein dimerization, and interac-
ting with Fe-S moieties or other metal complexes. In COPD these
post-translational mechanisms include the nitration of histone
deacetylase (HDAC) 2, leading to its inactivation and degrada-
tion resulting in the prolonged inﬂammatory phenotype seen in
patients [43,44]. Additionally, RNOS can modify various proteins,
rendering them auto-antigenic (i.e., immunoinﬂammatory) [45].
(Summarized in Fig. 1). Therefore oxidative stress can be a key cause
of both proliferation (lung cancer) and inﬂammation (COPD) in the
lungs.
7. Telomere shortening is a risk factor in COPD and lung
cancer
Telomeres are repetitive nucleotide sequences located at the
ends of the chromosomes which protect against the progressive
shortening that occurs with DNA replication. Telomere shortening
is associated with cell aging and senescence; with cells unable to
divide once their telomere shorten beyond a crucial point—termed
the Hayﬂick limit [46]. Once cells reach senescence the telomere
nucleoprotein loses structural integrity and cell division is arrested
in a process involving the tumor suppressor proteins p53 and
Retinobastoma protein (Rb), which regulate cell cycle progression
[46]. Entry of the cell into replicative senescence has been sug-
gested as a tumor suppressing mechanism, preventing replication
of cells most likely to form neoplasms.
Some cells, however, are able to bypass senescence through
inactivation of the Rb and p53 signaling pathways, enter ‘crisis’ and
continue to replicate [46]. Telomeres are critically short in these
cells and no longer protect the chromosome ends. The crisis phase
is characterized by genetic instability and widespread cell death by
apoptosis [46]. An immortalized clone of the cell (1 in 107 cells) can
emerge, which maintains telomere length through cell divisions.
Both COPD and lung cancer are associated with shortened telo-
mere length, and importantly telomere shortening can be driven
by cigarette smoking [47].
Several studies have shown a link between short telomere
length and the development of lung cancer [48–51] and poor prog-
nosis [51]. Similarly there is evidence that shorter telomeres are
associated with COPD [52] and short telomere length may  con-
tribute to inﬂammation in COPD [53]. Studies using murine models
have also shown that shortened telomeres increases susceptibil-
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Fig. 1. Reactive oxygen and nitrogen species (RNOS) derived from both exogenous and endogenous sources drive many of the pathways in both COPD and lung cancer. RNOS
can  react with DNA, leading to DNA damage, which if not correctly repaired leads to mutations. Mechanisms that prevent mutation, including DNA repair and apoptosis
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ty to emphysema [54]. Since telomere shortening is accelerated
y smoking, cells may  reach their Hayﬂick limit more rapidly and
nter replicative senescence causing COPD, or enter crisis where the
ccumulation of mutations leads to an immortalized cancer clone
ell.
. Genetic predisposition to lung cancer and COPD
There is evidence for familial susceptibility in both COPD and
ung cancer. This familial susceptibility appears to be linked and not
ust associated with the common consumption of cigarettes; imply-
ng that the underlying genetic predisposition to both diseases may
e the same or reﬂect the link between the immune system, inﬂam-
ation and cancer [55]. Linkage studies have implicated regions in
hromosome 6 as being linked to both diseases [55–57]. Further-
ore, GWAS studies in large COPD and lung cancer cohorts have
ound the same risk loci including CHRNA3 and CHRNA5 SNPs (15q)
nd regions at 4q31 (HHIP), 4q24 (FAM13A) and 5q (HTR4). Nico-
ine addiction may  explain the overlap in risk loci between lung
ancer, smoking behavior and COPD [58]. Epithelial to mesenchy-
al  transition (EMT) and inﬂammation are pathogenic features of
OPD and lung cancer and the rs7326277TT genotype in VEGFR1,
hich promotes inﬂammation, EMT  and tumor growth, is a suscep-
ible locus for both COPD and lung cancer [59]. Several studies have
emonstrated that polymorphisms in the anti-inﬂammatory gene
L10 are associated with increased rates of lung and other cancer
25,60].
. Epigenetics in lung cancer and COPD
In addition to genetic changes, epigenetic changes includ-
ng DNA methylation, covalent histone modiﬁcations, microRNAs
miRNAs) expression and nucleosome remodeling have also been
eported to play an important role in the development of cancer
61] and COPD [62]. DNA methylation, which is a reversible modi-
cation of DNA structure, adding a methyl group to the 5′ position
f a cytosine residue, often as part of a CpG island or cluster [63],
f tumor suppressor genes including APC, CDKN2, BRCA1, Rb and infection and drive inﬂammation in the lungs. Inﬂammation can lead to further
the action of cytokines and proteases. RNOS are capable of inhibiting the protective
ing cellular proliferation, which can in turn promote tumourgenesis.
MDM2  contributes to increased proliferation [64,65]. Hypermeth-
ylation of tumor suppressor and other gene promoters is observed
in the majority of lung cancers [66]. The reversible nature of pro-
moter hypermethylation makes it an attractive target for cancer
therapy.
Unsupervised hierarchical clustering of DNA methylation pat-
terns results in 3 lung cancer clusters [67]. Lung adenocarcinomas
in Cluster 1 developed from an inﬂammatory background in COPD
in heavy smokers and were locally invasive. Overall, DNA methyla-
tion proﬁles may  reﬂect carcinogenetic factors such as smoking and
COPD and may  distinguish patients with distinct types of NSCLC.
Recently an epigenome wide association study (EWAS) has
been carried out to examine links between gene methylation
in COPD and lung cancer [68]. This study identiﬁed that DNA
methylation and repression of 2 genes, CCDC37 and MAP1B,  was
signiﬁcantly associated with both COPD and lung cancer [68]. Fur-
thermore, COPD patients had a higher level of methylation and
gene repression than non-COPD patients with the greatest degree
of methylation seen in cancer patients with COPD.
Although alterations to DNA methylation have been examined
in COPD these are mostly linked to hypomethylation of immune-
modulatory genes [69] or in the SERPINA1 gene coding for alpha1-
antitrypsin [62] and linked to gene overexpression.
DNA coiling around histones is a dynamic process controlled by
histone acetylation and methylation and alterations to the activ-
ity to the enzymes which control this process can have a large
impact on gene expression. Histones are acetylated by histone
acetyl transferase proteins (HAT), which unwinds the DNA allow-
ing transcription: acetyl groups are removed by HDACs resulting in
gene silencing. Cigarette smoke reduces the expression and activ-
ity of HDAC2 both at the protein and mRNA level [70] and HDAC2
plays a key role in inﬂammation in COPD [71]. In contrast to COPD,
where therapeutic attempts to restore HDAC activity have been
trialed [72], HDAC inhibitors have been tested in lung cancer [73].
This may  reﬂect the relative importance of deacetylation of pro-
teins including p53, c-Myc, NF-B, HIF-1,  HSP90 [73] or that HDAC
inhibitors and HAT mimics may  produce similar cellular functions
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ue to non-selective histone acetylation preventing selective tran-
cription factor DNA binding [74].
Non-coding RNAs include microRNAs (miRNA), which are small
on-coding, single stranded RNA molecules, of 19–25 nucleotides
n length [75]. MiRNAs are capable of binding to full length mRNA
equences and alter their translation into protein. The effect of
nducing or repressing microRNA expression can inﬂuence most
iological processes, including cell fate speciﬁcation, cell prolif-
ration, DNA repair, DNA methylation and apoptosis and provide
ro-inﬂammatory or anti-inﬂammatory stimuli. Importantly, miR-
As play an essential role in the development of both the adaptive
nd innate immune system [76].
The interactions of miRNAs and mRNAs and their role in dis-
ase is not yet fully understood, but may  be potential drivers and
iomarkers of disease [77]. Several miRNAs are linked to both
nﬂammation and proliferation. For example miR-1 has been linked
o cigarette smoking-related conditions such as heart disease and
ancer [75] and is down-regulated in skeletal muscle of patients
ith COPD compared with non-smoking controls and expression
orrelated with clinical features [78]. miR-21 has been shown to
lay a role in both inﬂammation and cancer [25]. Another miRNA
iR-146a has been shown to downregulate both inﬂammation and
ancer cell proliferation [79].
0. COPD as a driver of lung cancer
COPD and lung cancer share many common pathways for acti-
ation, and inﬂammation and cancer are closely linked. As almost
ll cancerous tissues show inﬂammation and a number of inﬂam-
atory diseases can predispose to cancer [25,80], it is possible that
hat the chronic inﬂammation in COPD is a potent driver of lung
ancer development as evidenced by the efﬁcacy of non-steroidal
nti-inﬂammatories as anti-cancer treatments [25]. Inﬂammation
s a key source of RNOS [33] and RNOS levels are persistently high
n COPD.
Mitochondria are the major cellular source of RNOS [26] and the
itochondrial dysfunction seen in COPD [81] may  link COPD with
he development of lung cancer. Lung endothelial cell apoptosis
s regulated by the mitochondrial transcription factor A (mtTFA).
he gene for mtTFA is methylated in COPD patients with squamous
ell lung cancer leading to reduced expression and loss of normal
itochondrial function resulting in endothelial cell apoptosis [82].
Inﬂammatory mediators can inﬂuence the cancer micro-
nvironment, and the expression of cytokines is vital to drive the
mmune response to prevent cancer formation. For example IFN
nockout mice are more susceptible to carcinogens than wild-type
ice [83]. However inﬂammation can also drive carcinogenesis.
berrant cytokine signaling in chronic inﬂammation can drive cell
rowth differentiation and apoptosis [83]. Numerous cytokines
re associated with cancer development, for example macrophage
olony stimulating factor (M-CSF) has been linked to breast cancer
pread in mice models [84].
Increased IL-17 expression is associated with the severity of
OPD [85] and promotes chronic inﬂammation. In a murine model
f lung cancer, lack of IL-17A, but not IL-17F, reduced tumor cell
roliferation and inﬂammatory mediator expression [86]. This data
ighlights a possible novel approach to the treatment of COPD-
ssociated lung cancer.
Chronic inﬂammation is associated with the overexpression
f the transcription factor NF-B, which is a key mediator of
nﬂammation-induced carcinogenesis [87]. NF-B induces the
xpression of many pro-inﬂammatory cytokines such as IL1,  IL6,
L8 and TNF  ˛ as well that of key components of the cell cycle
ncluding the cyclins D1, D2, D3, E1 and various cyclin dependent
inases (CDKs) [87]. Additionally NF-B can contribute to cancino-ancer 90 (2015) 121–127
genesis by suppression of p53, by upregulating the levels of p53
E3 ligase, and thereby reducing p53 stability. Other cellular path-
ways which are involved in carcinogenesis also show cross-talk
with inﬂammatory pathways. The PI3K pathway is an important
driver of proliferation and the suppression of cell apoptosis and
is activated in COPD [88]. Aberrant expression of growth factors is
linked to tissue remodelling in response to cigarette smoke in COPD
patients and plays a role in lung cancer. For example, levels of EGF
receptors are higher in COPD patients [89] and in lung cancer [90].
Another common pathway to inﬂammation and proliferation
is the Wnt  pathway. Canonically the Wnt  proteins are extracellu-
lar messenger proteins that bind to the disheveled (Dsh) receptor
on the cells; this in turn leads to a signaling cascade that ultimately
leads to the buildup of the transcription factor -catenin. Activation
of Wnt  proteins and -catenin is increased in COPD patients [91]
and may  be linked to premature aging in the lungs [92]. As drivers
of development and cellular proliferation aberrant Wnt  pathway
activation is an important driver of many cancers and activation
of Wnt/Beta catenin pathway is associated with faster lung can-
cer development in mice [93]. However, whilst strongly linked to
other cancers, e.g., colon cancer [94], mutations in Wnt/APC are not
strongly associated with lung cancer.
The chronic inﬂammation in COPD also causes lung damage
which results in cell division in an effort to restore homeostasis. The
increased rate of cell division, especially if paired with increased
DNA damage due to smoking [22], greatly increases the probabil-
ity mutations thereby increasing the chance of carcinogenesis. The
repair processes in the lung include epithelial-mesenchymal transi-
tion (EMT), in which epithelial cells transform to mesenchymal cells
in order to translocate to the site of damage, where they revert to
epithelial cells. EMT  is driven by transforming growth factor (TGF)
and is a process has been linked to both COPD [95] and lung cancer
[96].
The physiological conditions within the lung caused by COPD,
rather than the chronic inﬂammation underlying the disease per se,
may also contribute to the development of lung cancer. The lungs
of COPD patients are hypoxic due to air trapping and reduced air
ﬂow. Hypoxic conditions stimulate the activation of the transcrip-
tion factor hypoxia inducible factor (HIF) 1-alpha. HIF-1  induction
is also seen in cancer cells due to the local hypoxic environment.
HIF-1 regulates over 200 genes and activates glycolysis, immortal-
ization through telomerase activation, stoppage of differentiation
and can inhibit apoptosis [36]. Recent comparisons of lipidomic
proﬁles in sputum from COPD patients [97] suggest that COPD
leads to changes in lipid proﬁles including increased ceramide lev-
els. These changes in lipid metabolism in turn, may alter other
physiological responses, including the hypoxia response and EGFR
signaling and may  play a role in the link between COPD and cancer
[97].
11. Therapeutic implications
Lung cancer remains one of the most fatal forms of cancer, both
due to lack of diagnosis and lack of effective treatments. Screening
of COPD patients for the development of cancer, for example
through CT scans, has been suggested as a potential method enable
early detection and thereby to improve outcomes. However, this
approach of increased surveillance is hampered by the lack of sensi-
tivity of treatment and the large numbers of false positive diagnoses
that result [16]. Potentially with improved understanding of the
links between the diseases more selective biomarkers will become
available making this approach viable.
It is increasingly recognized that, due to the range of drivers
of cancer, personalized medicine approaches based on the indi-
vidual’s cancer are important. For example patients can now be
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ested for alterations in Epidermal growth factor receptor (EGFR)
r vascular endothelial growth factor (VEGF) and, when appro-
riate treated with speciﬁcally targeted drugs for example EGFR
nhibitor Erlotinib [98] or, less successfully using VEGF binding
onoclonal antibodies, such as Ramucirumab [99]. The efﬁcacy
f these drugs depends upon the presence of receptor mutations
nd just as importantly it is likely that speciﬁc subphenotypes of
OPD will be susceptible to anti-inﬂammatory and/or antioxidant
herapies that will impact upon the incidence of lung cancer. The
ombination of selective biomarkers in carefully stratiﬁed at-risk
atients will be necessary to achieve optimal therapeutic effects.
It may  therefore be possible to, in future, treat COPD patients
ith speciﬁcally targeted therapies to reduce the risk of the patients
eveloping lung cancer. For example, owing to the important role
f oxidative stress in both diseases it has been suggested that
nti-oxidant therapy, for example vitamin C, vitamin E or N-acetyl
ysteine (NAC) [100], may  be of beneﬁt to patients, both reducing
xacerbations and inﬂammation and also reducing lung cancer inci-
ence. However, the results from trials of NAC treatment in COPD
re mixed often failing to improve quality of life or reduce exacer-
ations due to inadequate dosing [101]. Furthermore, recent work
n mice indicates that treatment with antioxidants was associated
ith an increased cancer risk in a COPD model [102].
The potential problems with the use of antioxidants to prevent
he development of lung cancer in all at risk patients highlights the
eterogeneity of both diseases and therefore the need to develop
peciﬁc, targeted treatments for the most at risk sub-populations
f COPD patients to prevent them from developing lung cancer. In
rder for such an approach to be feasible however we  will need to
ncrease our knowledge of both diseases and their links and identify
iomarkers to both improve screening for the most at risk patients
nd develop effective treatments.
2. Conclusions
Whilst the exact mechanism(s) underlying the increased inci-
ence of lung cancer in patients with COPD is currently unknown,
he two diseases are closely linked at a molecular level. Further
esearch to elucidate the relationship between these two diseases
ay  provide not only insights into the their development but may
lso create the possibility of cross-over treatments being devel-
ped, whereby anti-inﬂammatories developed for COPD may  be
eneﬁcial in lung cancer and anti-cancer drugs may  play a role in
he future treatment of COPD.
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